Inventor · disambiguated record
Kim Askew
Also filed as: ASKEW KIM · ASKEW KIM LYNETTE
7 granted patents·3 pending applications·10 citations·filing 2015–2025
77Inventor score
Top patents by PatentIndex Score
10 records- 0189US11167043B2Composition and methods for treatment of ornithine transcarbamylase deficiencyTRANSLATE BIO INC·Filed 2018·Granted Nov 9, 2021·4 cites·4 claims
- 0283US10493135B2Methods of treating tissue calcificationALEXION PHARMA INC·Filed 2015·Granted Dec 3, 2019·4 cites·20 claims
- 0374US11364284B2Methods of treating myointimal proliferationINOZYME PHARMA INC·Filed 2017·Granted Jun 21, 2022·2 cites·18 claims
- 0474US2025019677A1Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)INOZYME PHARMA INC·Filed 2024·Application pending·0 cites
- 0572US12268754B2Composition and methods for treatment of ornithine transcarbamylase deficiencyTRANSLATE BIO INC·Filed 2021·Granted Apr 8, 2025·0 cites·18 claims
- 0664US2025152739A1Composition and methods for treatment of ornithine transcarbamylase deficiencyTRANSLATE BIO INC·Filed 2025·Application pending·0 cites
- 0760US12134790B2Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)INOZYME PHARMA INC·Filed 2018·Granted Nov 5, 2024·0 cites·25 claims
- 0857US2022354933A1Methods of treating myointimal proliferationINOZYME PHARMA INC·Filed 2022·Application pending·0 cites
- 0946USRE49529EMethods of treating tissue calcificationINOZYME PHARMA INC·Filed 2015·Granted May 16, 2023·0 cites·29 claims
- 1029US10413597B2Methods of treating Mucopolysaccharidosis IIIB (MPSIIIB)ALEXION PHARMA INC·Filed 2015·Granted Sep 17, 2019·0 cites·10 claims
Join the waitlist — get patent alerts
Get an alert when Kim Askew files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →